Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARICOR: Clarithromycin in Stable Coronary Heart Disease
NCT00121550Phase 3Completed
- Sponsor
- Copenhagen Trial Unit
- Start
- Oct 1999
- Primary completion
- Apr 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronary heart disease (CHD) comparing Clarithromycin with Placebo (2 arms). Primary endpoint: Composite of death regardless of cause, non-fatal AMI, or unstable angina pectoris at 2 years. Started Oct 1999; status: completed.
02
Drugs
clarithromycin
03
Conditions
coronary heart disease (CHD)
Beyond the preview
Go deeper on NCT00121550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00121550.